Outlook Therapeutics Inc (NASDAQ: OTLK)’s stock price has gone rise by 1.41 in comparison to its previous close of 0.44, however, the company has experienced a -10.76% decrease in its stock price over the last five trading days. PennyStocks reported 2023-11-07 that If you’re looking for penny stocks to invest in right now, you’ve got your work cut out for you. That’s because the initial strategy when approaching cheap stocks is to trade them in the short term instead of holding them forever.

Is It Worth Investing in Outlook Therapeutics Inc (NASDAQ: OTLK) Right Now?

Moreover, the 36-month beta value for OTLK is 0.41. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 6 as “hold,” and 0 as “sell.”

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


The average price recommended by analysts for Outlook Therapeutics Inc (OTLK) is $3.92, which is $3.47 above the current market price. The public float for OTLK is 128.12M and currently, short sellers hold a 25.00% of that float. On November 16, 2023, OTLK’s average trading volume was 11.32M shares.

OTLK’s Market Performance

OTLK stock saw an increase of -10.76% in the past week, with a monthly gain of 12.42% and a quarterly increase of -68.69%. The volatility ratio for the week is 9.28%, and the volatility levels for the last 30 days are 22.41% for Outlook Therapeutics Inc (OTLK). The simple moving average for the last 20 days is -9.65% for OTLK’s stock, with a simple moving average of -58.50% for the last 200 days.

Analysts’ Opinion of OTLK

Many brokerage firms have already submitted their reports for OTLK stocks, with H.C. Wainwright repeating the rating for OTLK by listing it as a “Neutral.” The predicted price for OTLK in the upcoming period, according to H.C. Wainwright is $1 based on the research report published on August 31, 2023 of the current year 2023.

OTLK Trading at 31.11% from the 50-Day Moving Average

After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.02% of loss for the given period.

Volatility was left at 22.41%, however, over the last 30 days, the volatility rate increased by 9.28%, as shares sank -5.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +101.17% upper at present.

During the last 5 trading sessions, OTLK fell by -10.76%, which changed the moving average for the period of 200-days by -61.20% in comparison to the 20-day moving average, which settled at $0.4926. In addition, Outlook Therapeutics Inc saw -58.69% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at OTLK starting from Dagnon Terry, who sale 520,000 shares at the price of $1.14 back on Apr 20. After this action, Dagnon Terry now owns 653,058 shares of Outlook Therapeutics Inc, valued at $590,200 using the latest closing price.

Evanson Jeff, the Chief Commercial Officer of Outlook Therapeutics Inc, sale 267,000 shares at $1.11 during a trade that took place back on Jan 20, which means that Evanson Jeff is holding 745,975 shares at $296,370 based on the most recent closing price.

Stock Fundamentals for OTLK

The total capital return value is set at -348.41, while invested capital returns managed to touch -544.15. Equity return is now at value -827.71, with -145.33 for asset returns.

Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated 125.43 points at debt to equity in total, while total debt to capital is 55.64. Total debt to assets is 38.41, with long-term debt to equity ratio resting at 0.05. Finally, the long-term debt to capital ratio is 0.02.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.39.


To wrap up, the performance of Outlook Therapeutics Inc (OTLK) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.